Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.
about
Protein corona - from molecular adsorption to physiological complexityAggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.Uncertainty estimates of purity measurements based on current information: toward a "live validation" of purity methodsToward a molecular understanding of nanoparticle-protein interactionsMass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography.Hollow-fiber flow field-flow fractionation with multi-angle laser scattering detection for aggregation studies of therapeutic proteins.Physicochemical characterization of nanoparticles and their behavior in the biological environment.Transmission electron microscopy as an orthogonal method to characterize protein aggregates.Evaluation of Nanoparticle Tracking for Characterization of Fibrillar Protein AggregatesHydrodynamic size-based separation and characterization of protein aggregates from total cell lysates.Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a miceStrategies for the assessment of protein aggregates in pharmaceutical biotech product developmentLife cycle management of critical ligand-binding reagents.Production of prone-to-aggregate proteins.Physicochemical and functional characterization of vaccine antigens and adjuvants.A multiscale view of therapeutic protein aggregation: a colloid science perspective.Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.Particle sizing methods for the detection of protein aggregates in biopharmaceuticals.Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding.Two decades of publishing excellence in pharmaceutical biotechnology.Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin.Analyzing insulin samples by size-exclusion chromatography: a column degradation study.Taylor dispersion analysis compared to dynamic light scattering for the size analysis of therapeutic peptides and proteins and their aggregates.Visual Detection of Denatured Glutathione Peptides: A Facile Method to Visibly Detect Heat Stressed Biomolecules.Quantitative laser diffraction method for the assessment of protein subvisible particlesEffects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins.Resolving power of dynamic light scattering for protein and polystyrene nanoparticles.How bio-questionable are the different recombinant human erythropoietin copy products in Thailand?Sedimentation velocity analytical ultracentrifugation for characterization of therapeutic antibodies.Quantitative Correlation between Viscosity of Concentrated MAb Solutions and Particle Size Parameters Obtained from Small-Angle X-ray Scattering.Investigating effects of sample pretreatment on protein stability using size-exclusion chromatography and high-resolution continuum source atomic absorption spectrometry.Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.High-throughput screening of excipients intended to prevent antigen aggregation at air-liquid interface.Multiwavelength transmission spectroscopy revisited for the characterization of the protein and polystyrene nanoparticle mixtures.Supercritical synthesis of poly (2-dimethylaminoethyl methacrylate)/ferrite nanocomposites for real-time monitoring of protein release.Thermodynamic and fluorescence analyses to determine mechanisms of IgG1 stabilization and destabilization by arginine.
P2860
Q26853351-44AAB544-DBF5-46E5-8B48-42CAFD65104AQ30422151-B2DA7D74-6149-4372-BBCE-93A242744C0FQ30528376-9ADD8856-F979-4C60-B713-BE28B24A1100Q33639595-031AD4D9-40CA-44CE-9D51-EFA2BF787A75Q34127391-CE974015-14E9-4C4A-AFFA-7A57C277F602Q35066657-021391C0-95D1-450F-BA15-439B1BB179C8Q35190894-D810DE7D-D8DA-4A7E-B61C-F867819586A3Q35224074-387EBA6B-D617-4392-910C-6676D2060840Q35234396-B494DC86-F682-47D7-A16D-5C555CABED97Q36631756-CE13DD2C-9A0E-4344-938B-64671E323085Q37022207-5C2F23A1-A066-4D4B-B21C-9F1F3359CADEQ37174443-6020EB80-FFF3-4090-A2BD-0B15159376A6Q37802771-D5F6BA7D-2275-4EE1-98E8-8EFF802B134CQ38158185-76CAB11A-E640-4BEA-B5C9-D32AB9675D8EQ38161235-964969EE-117A-40CD-8262-A0A145B90731Q38202170-C6C1FB68-4A94-4994-82EA-9A26DC0FA4E5Q38378651-97E2A6DA-68D7-417A-970C-0893CB143B47Q38952689-99F98B14-1988-4B81-B1F5-C5309EDA40F4Q39093458-2A428094-B845-4FE2-B0EE-188B0DBB5EF4Q39175704-B46874C2-62DF-4579-928F-24839BFAAC58Q40002920-34BC04A9-541B-41F4-8CE0-EEEAB99ED1CAQ41624513-CA84177F-1775-42B1-B33D-CD54B8C7A569Q41767544-BAAD6C30-19B9-4F8F-B072-40B202EB1860Q41838506-222E4300-F066-4E36-BE22-E306D415F33EQ41880923-8FEA3EDD-6C83-4BB3-AB2C-59810E5363A3Q41965705-35A735CA-0576-4FFD-A7EF-F154A32F77B0Q43185460-DCD96DFF-C575-43AD-A4A6-99A47D94F3D1Q43924528-B2CB8BFA-9883-4570-B470-C0A064655159Q46120837-AD8AE0EA-7E98-4F8F-82B1-43D9E32479D7Q47247669-B9591FC7-22E0-4A64-B73E-525F490E0A73Q47380764-13275AE0-8BBB-4D41-99E5-6BEF6DB4B742Q47578347-F8DCFB43-F6C4-47FF-98D1-6E7B25D0CC9DQ50508037-C221EFA4-D9DE-474E-93FA-9A5B3DC469AAQ50542693-830D8B7A-5130-4588-ABCF-5A7D6CAF7DFFQ51037403-4846596B-0F3D-4BC7-8EE0-66713328D5E9Q53569728-CBDF40BA-9E20-4366-8704-83EC9C74615DQ53663332-A3005E8D-CDF3-4ED7-9D3C-68BE1D51C84E
P2860
Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography: essential need to use orthogonal methods to assure the quality of therapeutic protein products.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Potential inaccurate quantitat ...... therapeutic protein products.
@en
Potential inaccurate quantitat ...... therapeutic protein products.
@nl
type
label
Potential inaccurate quantitat ...... therapeutic protein products.
@en
Potential inaccurate quantitat ...... therapeutic protein products.
@nl
prefLabel
Potential inaccurate quantitat ...... therapeutic protein products.
@en
Potential inaccurate quantitat ...... therapeutic protein products.
@nl
P2093
P356
P1476
Potential inaccurate quantitat ...... therapeutic protein products.
@en
P2093
C Russell Middaugh
Daan J A Crommelin
Gerhard Winter
John F Carpenter
Wim Jiskoot
P304
P356
10.1002/JPS.21989
P407
P577
2010-05-01T00:00:00Z